Clinical Trial

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase I/II trial evaluating the effectiveness of adding neoadjuvant HDR-B prior to RALP for HR-PCa patients with selective AAB for decipher high risk or pathologically node positive patients. Patients with newly diagnosed, histologically confirmed, non-metastatic, HR-PCa who are scheduled to receive RALP will be eligible to participate in the study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-11.
Trial Details
NCT Number NCT07182279
Lead Sponsor The Methodist Hospital Research Institute
Conditions Prostate Cancer (Adenocarcinoma)
Enrollment 29 participants
Start Date 2025-08-01
Primary Completion 2026-11-14 (estimated)
Study Completion 2026-11-14 (estimated)
Updated on ClinicalTrials.gov 2026-03-09